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Introduction
Ketogenesis is the process by which ketone bodies (KB), 
during times of starvation, are produced via fatty acid 
metabolism. Although much feared by physicians, mild 
ketosis can have therapeutic potential in a variety of 
disparate disease states. Th  e principle ketones include 
acetoacetate (AcAc), β-hydroxybutyrate (BHB) and ace-
tone. In times of starvation and low insulin levels, ketones 
supply up to 50% of basal energy requirements for most 
tissues, and up to 70% for the brain. Although glucose is 
the main metabolic substrate for neurons, ketones are 
capable of fulﬁ  lling the energy requirements of the brain. 
Th  e purpose of the present review is to explore the 
physiology of ketone body utilization by the brain in 
health and a variety of neurological conditions, and to 
discuss the potential for ketone supplementation as a 
therapeutic option in traumatic brain injury (TBI).
Ketones, metabolism and the brain
Ketone metabolism
Ketones are by-products of fat metabolism and are 
produced in hepatic mitochondria [1]. More speciﬁ  cally, 
the three KB are: AcAc – if not oxidized to form usable 
energy, this is the source of the two other KB; acetone – 
not an energy source, but instead exhaled or excreted as 
waste; and BHB – not technically a ketone, but reversibly 
produced from AcAc.
Th  e precursor for the synthesis of ketones is acetyl 
coenzyme A (acetyl CoA), which is formed by β-oxida-
tion of free fatty acids in the liver. Th  e two important 
determinants of keto  genesis are the availability of acetyl 
CoA and the mobilization of fatty acids liberated from 
white adipose tissue during fasting or catechol  aminergic 
stress [2,3].
AcAc is the central ketone body. AcAc is reduced to 
BHB by β-hydroxybutyrate dehydrogenase (BHD) in a 
NADH-requiring reversible reaction [3]:
(R)-3-Hydroxybutyrate + NAD+  acetoacetate + 
NADH + H+
Th   e extent of this reaction depends on the state of the 
cellular pool of NAD+ [4]. When highly reduced, most or 
all ketones will be in the form of BHB. Th   e ratio of BHB 
to AcAc reﬂ  ects the redox state within the mitochondrial 
matrix [5]. BHB is nonvolatile and is chemically stable. 
Th   is ketone body’s only metabolic fate is interconversion 
with AcAc. Once synthesized, ketones diﬀ  use into the 
circulation.
Fate of circulating ketones
Plasma concentrations of circulating KB range from 
<0.1 mM/l in the postprandial state to as much as 6 mM/l 
during fasting, with levels reaching 25 mM/l in diabetic 
ketoacidosis [6-8]. Under normal dietary conditions, 
ketogenesis from fatty acids is at very low levels. Th  is  is 
attributable to the relatively high blood levels of the 
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levels of ketogenesis-promoting hormones, glucagon and 
cortisol [2]. One of the prerequisites for ketogenesis is 
therefore low levels of circulating insulin, as seen during 
starvation and diabetic ketoacidosis
Th  e fate of circulating KB is to be taken up by extra-
hepatic tissues, although 10 to 20% may be lost in the 
urine [8,9]. KB provide an energy source for several 
tissues including the brain, skeletal muscle, myocardium 
and liver, although the heart and kidney have the greatest 
capacity for utilization [10]. Th  e rate of utilization 
appears to be a function of the circulating plasma levels 
[11-13].
Ketones and critical illness
Th   e major illness associated by intensive care physicians 
with ketosis is diabetic ketoacidosis. Outside diabetic 
ketoacidosis, ketone measurement is not routinely per-
formed and has been largely used as a research tool to 
quantify cellular redox status. Th  e arterial ketone body 
ratio (AKBR) is utilized to reﬂ   ect the mitochondrial 
redox status of hepatic cells and may reﬂ  ect  cellular 
energy status in a number of conditions including hemor-
rhage, hypoxia, sepsis and hepatic resection [14]. Th  e 
AKBR (ratio of AcAc to BHB) reﬂ  ects the cellular NAD+/
NADH ratio, which cannot be measured directly and is 
linked to the phosphorylation potential of the cell (see 
equation above). In critically ill patients, the entry of 
acetyl CoA into the tricarboxylic acid cycle is limited. 
Acetyl CoA consequently combines with another mole-
cule of acetyl CoA to form acetoacetic acid, which in turn 
is converted to BHB leading to an altered NAD+/NADH 
ratio and a decreased AKBR [14,15]. A reduced AKBR is 
therefore a sign of an ineﬃ   cient tricarboxylic acid cycle. 
Th  e AKBR has also been used as an indirect marker of 
the hepatocellular functional status as the predominant 
site of metabolism of the ketones is in the liver.
Not surprisingly, metabolic failure at the cellular level 
is associated with worse clinical outcomes. A low AKBR 
is associated with poor outcomes in both animal and 
human models of illness. Yassen and colleagues measured 
the AKBR in 20 critically ill patients [15]. Th  ey  demon-
strated a progressive decrease in those patients with 
septic shock who died. In a study of critically ill heart 
failure patients, Limuro and colleagues noted a survival 
of only 15% of patients with AKBR <0.7 [16]. Dresing and 
colleagues found the AKBR to be signiﬁ  cantly lower in 
nonsurvivors than survivors in 30 polytrauma patients 
(0.6 vs. 1.3; P = 0.001) [17]. Levy and colleagues, however, 
failed to ﬁ  nd a diﬀ  erence in AKBR levels between sur-
vivors and nonsurvivors in their cohort of septic patients 
[18]. In conjunction with the lactate:pyruvate ratio, the 
AKBR may provide further insight into the cellular redox 
potential of critically ill patients.
Ketones and the brain
Glucose is the major fuel for the brain in humans on a 
balanced diet. More recently it was proposed that other 
substances such as lactate and pyruvate may be utilized by 
neurons to sustain their activity [19]. Furthermore, during 
times of starvation, the brain has the capacity to adapt to 
the use of ketones as its major energy source (and in the 
metabolic disease diabetes mellitus). In longstanding 
starvation, ketones can provide 60 to 70% of the energy 
needs of the brain [20]. Th  e 1.5 kg human brain utilizes 
100 to 150 g glucose per day and 20% of the total body 
oxygen consumption at rest [7]. Protein catabolism can 
supply somewhere between 17 and 32 g glucose per day, 
well below the minimum daily cerebral glucose require-
ments [21]. In fact, to supply suﬃ   cient glucose to support 
brain metabolic requirements from protein alone would 
lead to death in about 10 days instead of the 57 to 73 days 
[22]. Moreover in subjects undergoing total starva  tion for 
30 days, the decrease in hunger coincides with the 
elevation of blood ketones to 7 mM/l. During periods of 
ongoing starvation, an average-size person produces about 
150 g KB per day [23]. One should note, however, that 
ketones are incapable of maintaining or restoring normal 
cerebral function in the complete absence of glucose.
Astrocytes may play a signiﬁ  cant role in the regulation 
of brain energy metabolism [24]. Reports suggest that 
astrocytes can produce KB from fatty acids and leucine 
and are involved with other pathways of lipid metabolism, 
such as lipid synthesis and lipoprotein secretion [25-28]. 
Furthermore, it appears that the production of lactate 
and KB by astrocytes may increase secondary to neuro-
transmitters released during enhance synaptic activity 
[29,30].
Although the implications of ketone body production 
by astrocytes are still unclear, the fact that astrocytes 
outnumber neurons approximately 9:1 and occupy at 
least 50% of the cerebral volume suggests this constitutes 
a quantitatively important pathway in the brain [31].
Regulation of cerebral ketone uptake
As previously noted, humans can achieve very high 
circulating KB concentrations during prolonged fasting, 
up to 9 mM/l (range 5.8 to 9.7 mM/l) [20]. Th  e  plasma 
concentration of KB is a signiﬁ  cant factor aﬀ  ecting the 
rate of cerebral uptake. Th   e blood–brain barrier (BBB) is 
relatively impermeable to most hydrophilic substances, 
such as KB, unless they are transported by a carrier 
protein. A family of proteins involved in the transport of 
monocarboxylic acids such as lactic acid and pyruvate 
across cellular membranes, called monocarboxylic acid 
transporters (MCT1 and MCT2), are thought to play an 
integral role.
It is not yet understood how MCTs are regulated. KB 
are transported at diﬀ   erent rates, with the uptake of 
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tration [12]. Furthermore, prolonged fasting appears to 
increase the BBB uptake of ketones, with some researchers 
demonstrating an eightfold increase in the expression of 
MCT1 [32]. Similarly, Hasselbalch and colleagues 
reported a 13-fold increase in cerebral uptake of BHB in 
humans following several days of fasting [33]. In contrast, 
rapidly increasing plasma ketone concentrations do not 
lead to such a signiﬁ   cant increase in cerebral ketone 
uptake. Pan and colleagues noted a much smaller increase 
in cerebral ketone concentrations following a rapid 
intravenous infusion of BHB as compared with prolonged 
fasting, implying that MCT upregulation is partly 
dependent on the length of exposure to increased plasma 
ketone levels [34,35].
Once across the BBB, KB enter brain cells to support 
cellular energy requirements. Studies of the uptake of KB 
by brain cells suggest entry occurs by two mechanisms: 
diﬀ   usion and a carrier-mediated process. MCTs have 
been demonstrated on neurons and glial cells although 
their role here appears less signiﬁ  cant as compared with 
that on the BBB. Th  e impact of mitochondrial enzyme 
activity involved in ketone metabolism is less clear. 
Certainly, mitochondrial enzymes can be upregulated by 
increased levels of BHB, as has been demonstrated 
following exposure to ketones through starvation or a 
prolonged high-fat diet [12,36-39]. In summary, there-
fore, a prolonged high blood ketone concentration leads 
to an increased rate of cerebral ketone uptake and 
meta bolism.
Regional variation in ketone body metabolism
Data for the regional variation in ketone body metabo-
lism are based largely on animal studies. Hawkins and 
colleagues and Morris noted that KB uptake varies from 
one brain region to another [40,41]. Following an intra-
venous administration of radioactive BHB to adult rats, 
uptake was greatest in the cerebral cortex (deep layers), 
in the superior and inferior colliculi, and in regions where 
the BBB is absent [40,41]. Areas with a low metabolic rate 
such as the corpus callosum and other white-matter 
structures demonstrated greatly reduced uptake. 
Interestingly, the pattern of KB uptake resembled that of 
glucose, except in the superﬁ   cial layers of the cortex 
where glucose uptake was higher [42]. Similarly, MCT1 
expression in the brain may resemble the pattern of KB 
uptake with some exceptions as MCT1 is found on glia 
and neurons as well as on BBB epithelial cells and 
because the pituitary and pineal have no BBB.
Neuroprotective eff  ects of ketones
Neuroprotection is the mechanisms and strategies that, 
once implemented, may lead to salvage, recovery or re-
generation of the nervous system. Ketones may have a 
neuroprotective eﬀ  ect (see Figure 1). Ketones represent 
an alternative fuel for both the normal and the injured 
brain [43].
Firstly, BHB is more energy eﬃ   cient than glucose and 
can stimulate mitochondrial biogenesis via the upregu  la-
tion of genes encoding energy metabolism and mitochon-
drial enzymes [44]. Th   ere is a marked increase in the free 
energy of ATP hydrolysis, as demonstrated by a 25% 
increase in hydrolytic work of isolated rat perfused heart 
preparations when exposed to KB [45]. Also, ketones 
increase the intermediary metabolites delivered to the 
citric acid cycle with a 16-fold elevation in acetyl CoA 
content.
Secondly, ketones protect against glutamate-mediated 
apoptosis and necrosis through the attenuation of the 
formation of reactive oxidant species. Ketones can 
oxidize coenzyme Q, thus decreasing mitochondrial free 
radical formation. Additionally, the reduction of NAD 
favors reduction of glutathione, which ultimately favors 
destruction of hydrogen peroxide by glutathione per-
oxidase reaction [46,47].
Th  irdly, ketones enhance the conversion of glutamate 
to GABA with the subsequence enhancement of GABA-
mediated inhibition [48,49]. Cerebral ketone uptake also 
increases cerebral blood ﬂ  ow [50].
Fourthly, cell death from apoptosis is attenuated by 
ketone ingestion [48]. Mechanisms include reductions in 
activation of caspase-3, increases in calbindin and 
preven  tion of accumulation of the protein clusterin.
Lastly, cerebral ketone metabolism alters cerebral blood 
ﬂ   ow [50]. Hasselbalch and colleagues demonstrated a 
39% increase in cerebral blood ﬂ  ow following an infusion 
of sodium BHB.
Current state of research – changes in ketone 
metabolism during brain injury
Models of injury – animal studies
Adaptive changes to cerebral ketone metabolism during 
development and starvation are well documented. How-
ever, there is evidence that other conditions including 
TBI, ischemia, hemorrhagic shock and hypoxia induce 
rapid changes in both vascular and cellular transporters 
that favor ketone uptake and metabolism. In addition, 
ketone-metabolizing enzymes demonstrate the ability to 
change in response to neuropathologic conditions. 
Collectively, these adaptations suggest that the brain may 
be more receptive to ketone metabolism under neuro-
pathic conditions.
Researchers have demonstrated an increase in MCT1 
and MCT2 expression following cerebral injury [51]. 
Similarly, ketone-metabolizing enzyme expression also 
appears to alter. Utilization of BHB in the brain is 
contingent on its con  version to AcAc by BHD, which is 
scarce in the adult brain, especially in the basal ganglia. 
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following cerebral insult [52].
Th   e brain’s ability to utilize exogenous KB is altered. At 
times of oxidative stress, the ability of the brain to use 
glucose as a substrate for metabolic activity may become 
compromised. Certainly, hyperglycemia has been 
repeatedly shown to be deleterious to the injured brain 
[53]. During these times, an exogenous supply of ketones 
may force the brain to shift its reliance from glucose to 
ketones, thus taking advantage of improved transport 
and cellular metabolism. Th   is shift can be advantageous 
in both acute brain injury models (glutamate excito-
toxicity, hypoxia/ischemia, TBI) and neurodegenerative 
conditions (Parkinson’s disease, Alzheimer’s disease).
Extensive research has been performed using the 
glutamate-induced injury model, the cerebral hypoxia 
model and the ischemic injury model. Glutamate neuro-
toxicity is implicated in a number of neurodegenerative 
disorders associated with brain ischemia, hypoglycemia 
and cerebral trauma. During injury, glutamate and 
aspartate are released through the reverse action of their 
transport systems or via enhanced exocytotic release. 
Th   is in turn leads to excitotoxicity and the production of 
reactive oxidant species. Administration of ketones 
appears to limit the extent of damage [54-58].  For 
example, Massieu and colleagues demonstrated that AcAc 
eﬀ  ectively protects against glutamate neurotoxicity both 
in vivo and in vitro in rats chronically treated with a 
glycolysis inhibitor [55].
Hypoxic/ischemic injury leads to a decrease in oxida-
tive metabolism by reducing oxygen availability [59,60]. 
Ketone administration ameliorates many of the sequelae 
of this process, including lactate generation, free radical 
damage and apoptotic cascade activation [61,62]. Suzuki 
and colleagues demonstrated that BHB prolonged the 
survival time in rat models of hypoxia, anoxia and 
global ischemia [63]. Th  ey further showed that BHB 
reduced infarct size after middle cerebral artery 
occlusion, irres  pective of whether BHB administration 
was delayed.
Figure 1. Potential neuroprotective mechanisms of ketones. Ketones (1) require only three enzymatic steps to enter the tricarboxylic acid 
(TCA) cycle, (2) reduce the NAD couple, (3) decrease free radical formation, (4) increase production of ATP, (5) increase mitochondrial uncoupling, 
(6) increase glutathione peroxidase activity, and (7) inhibit pyruvate entry into the TCA cycle. CoA, coenzyme A; GSH, reduced glutathione; GSSG, 
oxidized glutathione; NAD+, nicotinamide adenine dinucleotide; NADH, nicotinamide adenine dinucleotide hydrogenase; NADP, nicotinamide 
adenine dinucleotide phosphate; NADPH, nicotinamide adenine dinucleotide phosphate hydrogenase; OHB, hydroxybutyrate; PPP, pentose 
phosphate pathway; UCP, uncoupling protein. Reprinted with permission from [43].
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[64,65]. TBI is associated with impaired cerebral energy 
production with prolonged glucose metabolic depression 
and reduction of ATP. Cerebral injury is further exacer-
bated by free radical production, and activation of poly-
ADP-ribose polymerase via DNA damage [66]. As such, 
under these conditions of impaired glycolytic metabo-
lism, shifting the brain toward ketone metabolism may 
limit the extent of cerebral injury [63,67-70] (see Table 1). 
Much of this work is attributable to Prins and colleagues, 
who demonstrated that administration of intravenous 
BHB after TBI in adult rats led to an increase in uptake of 
BHB and alleviated the decrease in ATP after injury. In a 
subsequent study they found that a ketogenic diet was 
eﬀ  ective in reducing the cortical contusion volume in a 
rat model of TBI [64,65].
Neurodegenerative conditions may also beneﬁ  t from 
ketone administration as there is evidence of altered 
cerebral metabolism. Studies of Parkinson’s disease and 
Alzheimer’s disease conﬁ  rm the encouraging eﬀ  ects of 
ketones. Mechanisms are complex but include decreasing 
free radical production and providing acetyl CoA for 
energy production [45,52,71-74]. Other conditions that 
may be responsive to ketones include amyotrophic lateral 
sclerosis and certain brain tumors.
Models of injury – human research
Mild ketosis is induced in humans by either fasting or the 
consumption of a high-fat, low-carbohydrate diet. Most 
studies in humans have delivered ketones via the enteral 
route [75]. In adults, achieving blood levels of 5 to 
7  mM/l total KB requires the production or intake of 
about 150 g per day [23]. Th   is level, however, is subject to 
the inﬂ  uences of glucose, insulin, cortisol and catechol-
amines. To achieve a therapeutic response in refractory 
epilepsy, it has been suggested that the level of blood 
ketone should be above 4 mM/l [76].
Salts of KB can be produced. Several authors (see 
below) have administered sodium AcAc or sodium BHB 
successfully with few side eﬀ   ects. A new formulation 
Table 1. Animal and basic science studies on eff  ects of ketone administration on brain injury
Mechanism of injury Reference Ketone source Study Outcome
Glutamate-induced 
injury
Massieu and colleagues [55] i.v. AcAc infusion for 14 days in adult 
rodent model prior to and during 
glutamate-induced injury
Decreased neuronal damage, 
decreased lesion volume and 
increased cellular ATP levels
Noh and colleagues [57,58] p.o. 21-day-old mice fed ketogenic diet 
prior to kianic-induced neuronal 
damage
Preservation of neurons in 
hippocampus by inhibiting caspase-
3-mediated apoptosis
Mejia-Toiber and colleagues 
[56]
In vivo BHB applied before glutamate-induced 
neurotoxicity
BHB reduces injury and 
lipoperoxidation
Maalouf and colleagues [54] In vivo Addition of BHB to in vitro model of 
glutamate neurotoxicity
Reduction in free radical formation 
and enhanced mitochondrial 
respiration
Cerebral hypoxia Puchowicz and colleagues [60] p.o. Rats fed ketogenic diet 3 weeks prior to 
hypoxic injury
Decreased cerebral lactate and 
increased tolerance of hypoxia
Masuda and colleagues [59] In vivo Rat neurons exposed to hypoxia 
following treatment with BHB
Decreased cell death and number of 
apoptotic cells with maintenance of 
mitochondrial membrane
Cerebral ischemia Suzuki and colleagues [70] i.v. Rats infused with BHB 3 to 6 hours after 
bilateral carotid artery occlusion
Decreased cerebral edema and 
sodium content and increased ATP 
levels
Suzuki and colleagues [63] i.v. BHB infusions following occlusion of 
the middle cerebral artery
50% reduction in cerebral infarct 
volume
Marie and colleagues [69] Fasted Adult rats fasted for 24 hours before 
four-vessel occlusion
Decreased mortality, post-traumatic 
seizures and brain lactate
Go and colleagues [68] Fasted Starvation-induced ketosis followed by 
carotid occlusion
Fasting protected rats from brain 
infarction
Traumatic brain injury Prins and colleagues [65] i.v. BHB infusion following TBI in adult rats Increase in serum BHB and cerebral 
BHB and improved cortical ATP levels
Prins and colleagues [64] p.o. Rats with TBI fed ketogenic diet 50% reduction in cortical contusion 
volume
Biros and Nordness [67] p.o. Rats of diff  ering ages fed ketogenic diet 
following TBI
Younger rats demonstrated larger 
reduction in contusion volume
Hu and colleagues [61,62] p.o. Rats fed ketogenic diet prior to TBI Reduced brain edema and cellular 
apoptosis in rats fed ketone diet
AcAc, acetoacetate; BHB, β-hydroxybutyrate; In vivo, in vivo experiment; i.v., intravenous; p.o., per orally; TBI, traumatic brain injury.
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BHB, although relevant concentrations are not described 
[77]. Th   e main issues related to intravenous adminis  tra-
tion of ketone solutions include volume loading, sodium 
loading and the potential for signiﬁ  cant  meta  bolic 
alkalosis. Th  ese issues will depend on the relevant 
concentrations of anions and cations in the mixture and 
on the osmolality.
Th   ere is a paucity of research examining the eﬀ  ects of 
ketone administration in humans. Interpretation of results 
is further complicated by variable routes of adminis-
tration, concentrations and age variability of research 
subjects. For instance, research on the eﬀ  ects of intra-
enous ketone preparations are conﬁ   ned almost exclu-
sively to adults, whereas dietary studies include a large 
number of children. As far as we are aware, only two 
clinical studies examining the neuroprotective eﬀ  ects of 
KB in humans have been undertaken. Th  e  ﬁ  rst by Ritter 
and colleagues examined the eﬀ  ects of a ketogenic diet 
on biochemical markers of metabolism in head-injury 
patients but did not include clinical outcomes [78]. Th  e 
second study, reported by Smith and colleagues, has 
never been published but the authors reported on the use 
of a sodium BHB solution for neuroprotection during 
cardiac surgery [77]. Th   e bulk of the research has taken 
place using the rodent model.
Some general statements, however, can be made. 
Studies have demonstrated that ketones can be given 
enterally or intravenously with minimal side eﬀ  ects; that 
utilization of KB increases with rising blood concen  tra-
tions, with a plateau at approximately 128 g/24 hours; 
that hyperketotic states are associated with improved 
glucose control; that increased plasma levels lead to an 
increase in cerebral uptake; and that ketogenic diets may 
lead to improved cognitive function in patients with 
chronic dementia (see Table 2). Well-designed outcome 
studies, however, are lacking [34,35,77-85].
Adverse eff  ects of ketones
Th   ere are minimal data on the adverse eﬀ  ects of ketone 
administration, much of which are based on chronic 
intake via the enteral route rather than the parenteral 
route. In the acute setting, eﬀ  ects of parenteral formu-
lations on the pH, sodium level, lipids and glucose are 
likely to dominate; for example, intravenous formulations 
would theoreti  cally be alkalinizing, depending on the 
ketone concen  tration. Th   is was conﬁ  rmed by Hiraide and 
colleagues, who noted a signiﬁ    cant increase in pH and 
sodium concentrations following the intravenous adminis-
tration of a 20% solution of sodium BHB to severe trauma 
patients [81]. Also of potential concern is the reduction 
in glucose cerebral metabolism and the increase in 
cerebral blood ﬂ   ow demon  strated by Hasselbalch and 
colleagues during adminis  tration of intravenous BHB 
[50]. Th  e long-term consequences of these changes are 
not yet known.
Some side eﬀ   ects are predictable following enteral 
administration, such as dehydration and hypoglycemia. 
Other side eﬀ  ects are less common and present following 
prolonged use, including growth retardation, obesity, 
nutrient deﬁ   ciency, decreased bone density, hepatic 
failure, and immune dysfunction. Freeman and colleagues 
reported a signiﬁ  cant rise in mean blood cholesterol to 
over 250 mg/dl following prolonged intake a of ketogenic 
diet [86]. Th  is  eﬀ  ect in turn may be atherogenic, leading 
to lipid deposition in blood vessels. In addition there are 
reports of dilated cardiomyopathy in patients on the 
keto  genic diet, possibly as a consequence of the toxic 
eﬀ   ects of elevated plasma free fatty acids. Finally, an 
increased incidence in nephrolithiasis in patients on the 
ketogenic diet as well as increases in serum uric acid 
secondary have been reported [66,87].
Potential clinical applications for ketone 
solutions – traumatic brain injury
TBI is a major cause of mortality and morbidity in young 
adults [88]. Cerebral edema and subsequent intracranial 
hypertension is an important factor inﬂ  uencing patient 
outcome, and, despite considerable research, has proven 
diﬃ   cult to manage. Over the past 30 years, osmotherapy 
has become an important tool in the management of 
intracranial hypertension after TBI [88]. Various sub-
stances, including urea, glycerol, sorbitol and mannitol, 
have been utilized [89,90]. More recently, hypertonic 
saline (HTS) has proven useful in controlling intracranial 
pressure (ICP).
HTS has been extensively studied in animal and human 
models of TBI [91-94]. Th  ese experiments suggest that 
small-volume resuscitation with HTS solution may be 
beneﬁ  cial for increasing cerebral perfusion pressure and 
cerebral blood ﬂ  ow and for decreasing ICP while main-
tain  ing hemodynamic stability following TBI. Animal 
studies comparing HTS and mannitol suggest that HTS is 
more eﬀ  ective in reducing ICP and has a longer duration 
of action [95,96]. In humans, HTS appears eﬀ  ective for 
reducing ICP in cases of refractory intracranial hyper-
tension following TBI. Several studies have conﬁ  rmed a 
signiﬁ  cant decrease in ICP correlated with an increasing 
serum osmolality [97-99].
In the past, researchers have combined hypertonic 
sodium with a variety of anions including acetate and 
lactate [100,101]. Acetate, a source of hydrogen ion accep-
tors, is an alternate source of bicarbonate by meta  bolic 
conversion in the liver. Acetate is a myocardial depres-
sant, however, and can lead to hypotension in susceptible 
individuals. Hypertonic sodium/lactate solutions have 
also been investigated. Whilst HTS/lactate is generally 
considered safe and may provide cerebral nutrition, there 
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lactate may be associated with signiﬁ  cant toxic eﬀ  ects 
[102]. Further research is required to clarify these issues.
Th   ere is therefore a need for a solution able to address 
two fundamental problems related to TBI; namely, refrac-
tory intracerebral hypertension and low cerebral energy 
levels. Th  is requirement could theoretically be accom-
plished by incorporating ketones into a hypertonic 
solution such as HTS. Th  ere are, however, a number of 
challenges asso  ciated with the development of new 
parenteral solutions.
Firstly, the impact of the constituents on individual 
metabolism needs to be evaluated. Th  e hypertonicity 
induced by 3% NaCl is well documented and desirable. 
Th  e target sodium level is not known, however, and 
various authors have reported levels as high as 
185 mmol/l. Secondly, although the long-term metabolic 
eﬀ   ects of ketone administration are described, little 
infor  mation exists on the acute changes induced by 
intravenous infusions. For example, the entry of ketones 
into cerebrospinal ﬂ  uid is partly concentration dependent 
and therefore a certain serum level (possibly above 
Table 2. Human studies investigating eff  ects of exogenous ketone administration
Pathophysiological 
endpoint Reference Study Outcome
Metabolic eff  ects Owen and colleagues 
[83]
Eff  ect of ketones on insulin and free fatty acid 
release. Sodium AcAc given as i.v. infusion 
1 mmol/kg over 2 hours to 12 normal adults after 
overnight fast
AcAc levels 4.74 mmol/l after 30 minutes. 
Utilization of ketones increased with rising blood 
concentrations to a maximum of 13 g/24 hours. 
Glucose remained normal
Miles and colleagues 
[82]
Evaluation of protein-sparing eff  ects of i.v. infusion 
of NaBHB in six healthy adults
Ketone levels reached 2.33 mmol/l. No protein 
sparing, signifi  cant alkalosis
Hiraide and colleagues 
[81]
Twenty patients following severe trauma: 11 
patients received i.v. 20% solution NaBHB at 
25 μmol/kg/minute for 3 hours, and nine patients 
received sodium lactate
Ketone levels reached 1.5 mmol/l. Alanine 
release decreased in ketone group, suggesting 
a suppression of post-traumatic protein 
catabolism. Signifi  cant increase in sodium and 
pH
Dashti and colleagues 
[80]
64 healthy obese adults with and without diabetes 
fed ketogenic diet for 56 weeks
Body mass index, glucose, total and low-density 
lipoprotein cholesterol decreased signifi  cantly 
whereas high-density lipoprotein increased
Central nervous system 
eff  ects
Pan and colleagues [35] Six healthy adults infused with NaBHB at a bolus 
rate of 80 μmol/kg/minute, then 20 μmol/kg/
minute for 75 minutes. BHB brain levels measured 
by MRI
BHB blood levels reached 2.12 mmol/l. BHB brain 
levels increased to 0.24 mmol/l. Levels lower 
then noted in fasted individuals suggesting 
diff  erences in brain transport of ketones in fasted 
state
Pan and colleagues [34] Five healthy adults. Ketones measured in brain 
using MRI in nonfasted state and after 2 and 3 days 
of fast
Plasma and brain BHB levels correlated well, with 
brain BHB ranging from 0.05 mmol/l in nonfasted 
state to 0.98 mmol/l after 3 days of fasting
Blomqvist and colleagues 
[79]
Six healthy and six diabetic patients received 
infusion of BHB at 3 to 6 mg/kg/minute for 
60 minutes followed by bolus of B-[11C]HB. PET 
scan was performed
Utilization rate of ketones increase proportionally 
with plasma concentrations. Rate-limiting step 
for ketone body utilization is transport into the 
brain
Hasselbalch and 
colleagues [85]
Permeability of blood–brain barrier to BHB was 
assessed following a 3.5-day fast
Increase cerebral ketone infl  ux during starvation 
determined by amount of ketone present in 
blood
Ritter and colleagues 
[78]
Twenty head-injured patients assigned to 
conventional or ketogenic diet for 2 weeks
Group receiving a ketogenic diet demonstrated 
improved glucose control with higher ketone 
levels. Cerebral lactate was similar
Smith and colleagues 
[77]
NaBHB i.v. solution known as KTX 0101 for 
neuroprotection post CABG. Details of study 
protocol not available
Phase Ia study not published
Hasselbalch and 
colleagues [50]
Eight healthy adults received i.v. infusion of NaBHB 
at 4 to 5 mg/kg/minute for 3 hours. Cerebral blood 
fl  ow measured using Kety–Schmidt technique
Increased cerebral uptake of ketones was 
counterbalanced by reduction in glucose 
metabolism. Cerebral metabolic rate was 
unchanged, but cerebral blood fl  ow increased
Reger and colleagues 
[84]
Twenty adults with Alzheimer’s disease were 
randomized to receive a MCT diet or placebo on 
two occasions
On cognitive testing, MCT treatment facilitated 
performance for ε4-negative but not ε4-positive 
subjects. Also greater improvement with MCT 
treatment relative to placebo
AcAc, acetoacetate; B-[11C]HB, R-β-[1-11C]hydroxybutyrate; BHB, β-hydroxybutyrate; CABG, coronary artery bypass graft; i.v., intravenous; MCT, medium chain 
triglycerides; MRI, magnetic resonance imaging; NaBHB, sodium β-hydroxybutyrate; PET, positron emission tomography.
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Page 7 of 104 mM/l) is required for maximum utilization. What then 
is the eﬀ  ect of high ketone concentration on blood pH? 
Such a solution would be expected to be alkalinizing, but 
this will be altered by the rate of metabolism. Th  irdly, 
which ketone should be incorporated, AcAc or BHB? 
Both ketones have been administered to humans in the 
past without ill eﬀ   ects. Fourthly, should cerebrospinal 
ﬂ  uid or plasma levels be utilized to guide therapy? Lastly, 
ketones are expensive to produce, so can a commercially 
viable solution be developed?
Conclusion
Th  ere is both theoretical and clinical evidence that 
administering ketones to patients with cerebral injury 
may provide signiﬁ  cant beneﬁ  t. Furthermore, combining 
ketones with HTS may provide the added advantage of 
ICP control with improved cerebral metabolism. Th  ere 
are, however, a number of outstanding questions requir-
ing further consideration. Th   ese questions include 
dosing, timing, and the route and duration of adminis-
tration. Further research is necessary to clarify these 
issues and to determine whether an HTS ketone solution 
could be employed in the management of acute brain 
injury.
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